# Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

> **NCT06079671** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 800 (estimated)

## Conditions studied

- Locally Advanced Cervical Cancer

## Interventions

- **BIOLOGICAL:** Volrustomig
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06079671
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-22
- **Primary completion:** 2027-11-26
- **Final completion:** 2030-09-30
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06079671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06079671, "Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06079671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*